Skip to main content

Advertisement

SpringerLink
Log in

Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

There are a limited number of studies investigating the type of serum proteins capable of differentiating intraductal papillary mucinous neoplasms from benign or malignant diseases of the pancreas.

Aims

To select proteins able to differentiate intraductal papillary mucinous neoplasms from benign and malignant pancreatic disease using semiquantitative proteomics.

Methods

Serum samples were obtained from 74 patients (19 with type II intraductal papillary mucinous neoplasms, 8 with type I/III intraductal papillary mucinous neoplasms, 24 with chronic pancreatitis, 23 with pancreatic ductal adenocarcinomas) and 21 healthy subjects. Small proteins and peptides were assayed by matrix-assisted laser desorption/ionization for the detection of differentially abundant species possibly related to tumor onset. Serum pancreatic amylase, lipase, carcinoembryonic antigen and carbohydrate antigen 19-9 (CA 19-9) were also assayed.

Results

Twenty-six of 84 peaks detected were dysregulated (7 more abundant and 19 less abundant in the type II intraductal papillary mucinous neoplasms, p < 0.05). Of the differentially abundant peaks, 17 were commonly dysregulated (3 peaks more abundant and 13 less abundant in type II intraductal papillary mucinous neoplasms, and one at  m/z = 9961 at variance), indicating a protein fingerprint shared by types I/III and type II intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinomas.

Conclusions

These results suggest that our approach can be used to differentiate type II intraductal papillary mucinous neoplasms from type I/III neoplasms, and type II intraductal papillary mucinous neoplasms from pancreatic ductal adenocarcinomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Buscarini E, Pezzilli R, Cannizzaro R, et al. Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Dig Liver Dis. 2014;46:479–493.

    Article  PubMed  Google Scholar 

  2. Falconi M, Crippa S, Chari S, et al. Quality assessment of the guidelines on cystic neoplasms of the pancreas. Pancreatology. 2015;15:463–469.

    Article  PubMed  Google Scholar 

  3. Capurso G, Boccia S, Salvia R, et al. Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case–control study. Am J Gastroenterol. 2013;108:1003–1009.

    Article  PubMed  Google Scholar 

  4. Pezzilli R, Melzi dʼEril G, Barassi A. Can serum pancreatic amylase and lipase levels be used as diagnostic markers to distinguish between patients with mucinous cystic lesions of the pancreas, chronic pancreatitis, and pancreatic ductal adenocarcinoma? Pancreas. 2016;45:1272–1275.

    Article  CAS  PubMed  Google Scholar 

  5. Pezzilli R, Calculli L, Melzi d’Eril G, et al. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes. Hepatobiliary Pancreat Dis Int.. 2016;15:553–557.

    Article  PubMed  Google Scholar 

  6. Rebours V, Le Faouder J, Laouirem S, et al. In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms. Pancreatology. 2014;14:117–124.

    Article  CAS  PubMed  Google Scholar 

  7. Corcos O, Couvelard A, Dargère D, et al. Proteomic assessment of markers for malignancy in the mucus of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2012;41:169–174.

    Article  CAS  PubMed  Google Scholar 

  8. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.

    Article  PubMed  Google Scholar 

  9. Fania C, Vasso M, Torretta E, et al. Setup for human sera MALDI profiling: the case of rhEPO treatment. Electrophoresis. 2011;32:1715–1727.

    Article  CAS  PubMed  Google Scholar 

  10. Dudeja GV, Allen PJ. Premalignant cystic neoplasms of the pancreas. Semin Oncol. 2015;42:70–85.

    Article  PubMed  Google Scholar 

  11. Ohtsuka T, Matsunaga T, Kimura H, et al. Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines 2012. World J Surg. 2014;38:2994–3001.

    Article  PubMed  Google Scholar 

  12. Tamura K, Ohtsuka T, Ideno N, et al. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review. Ann Surg. 2014;259:360–368.

    Article  PubMed  Google Scholar 

  13. Pezzilli R, Corsi MM, Barassi A, et al. The role of inflammation in patients with intraductal mucinous neoplasm of the pancreas and in those with pancreatic adenocarcinoma. Anticancer Res. 2010;30:3801–3805.

    PubMed  Google Scholar 

  14. Salvia R, Malleo G, Marchegiani G, et al. Pancreatic resections for cystic neoplasms: from the surgeon’s presumption to the pathologist’s reality. Surgery. 2012;152:S135–S142.

    Article  PubMed  Google Scholar 

  15. Crippa S, Pezzilli R, Bissolati M, et al. Active surveillance beyond 5 years is required for presumed branch-duct intraductal papillary mucinous neoplasms undergoing non-operative management. Am. J. Gastroenterol. 2017. (in press).

  16. Pezzilli R, Fabbri D, Corsi MM, et al. Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study. Clin Chem Lab Med. 2011;49:1047–1051.

    Article  CAS  PubMed  Google Scholar 

  17. Velstra B, Vonk MA, Bonsing BA, et al. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques. J Cancer Res Clin Oncol. 2015;141:531–541.

    Article  CAS  PubMed  Google Scholar 

  18. Xue A, Scarlett CJ, Chung L, et al. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer. 2010;103:391–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Potjer TP, Mertens BJ, Nicolardi S, et al. Application of a serum protein signature for pancreatic cancer to separate cases from controls in a pancreatic surveillance cohort. Transl Oncol.. 2016;9:242–247.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cecconi D, Palmieri M, Donadelli M. Proteomics in pancreatic cancer research. Proteomics. 2011;11:816–828.

    Article  CAS  PubMed  Google Scholar 

  21. Liu Z, Ma Y, Yang J, et al. Upregulated and downregulated proteins in hepatocellular carcinoma: a systematic review of proteomic profiling studies. OMICS. 2011;15:61–71.

    Article  PubMed  Google Scholar 

  22. Zapico-Muñiz E, Farré-Viladrich A, Rico-Santana N, et al. Standardized peptidome profiling of human serum for the detection of pancreatic cancer. Pancreas. 2010;39:1293–1298.

    Article  PubMed  Google Scholar 

  23. Gerdtsson AS, Malats N, Säll A, et al. A multicenter trial defining a serum protein signature associated with pancreatic ductal adenocarcinoma. Int J Proteom. 2015;2015:587250.

    Article  Google Scholar 

  24. Yoneyama T, Ohtsuki S, Honda K, et al. Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS ONE. 2016;11:e0161009.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kikkawa S, Sogawa K, Satoh M, et al. Identification of a novel biomarker for biliary tract cancer using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Int J Proteomics.. 2012;2012:108609.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Hart PA, Topazian M, Raimondo M, et al. Endoscopic pancreas fluid collection: methods and relevance for clinical care and translational science. Am J Gastroenterol. 2016;111:1258–1266.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem. 2008;54:1608–1616.

    Article  CAS  PubMed  Google Scholar 

  28. Fania C, Sogno I, Vasso M, et al. A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification. Clin Chim Acta. 2015;439:42–49.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Enrica Torretta of the Department of Biomedical Sciences for Health, University of Milan, Milan, Italy, for the revision of statistical analyses.

Funding

This work was funded by the Italian Ministry of University and Scientific Research (Grant No. FIRB RBRNO78MCT to C. Gelfi).

Author information

Authors and Affiliations

  1. Clinical Proteomics Unit, IRCCS Policlinico San Donato, San Donato Milanese, MI, Italy

    Chiara Fania

  2. Pancreas Unit, Department of Digestive System, Sant’Orsola-Malpighi Hospital, Via Massarenti, 9, 40138, Bologna, Italy

    Raffaele Pezzilli

  3. Department of Health Sciences, San Paolo Hospital, University of Milan, Milan, Italy

    Gianvico Melzi d’Eril & Alessandra Barassi

  4. Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

    Cecilia Gelfi

Authors
  1. Chiara Fania
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raffaele Pezzilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gianvico Melzi d’Eril
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cecilia Gelfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessandra Barassi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raffaele Pezzilli.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 33 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fania, C., Pezzilli, R., Melzi d’Eril, G. et al. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma. Dig Dis Sci 63, 920–933 (2018). https://doi.org/10.1007/s10620-018-4944-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-018-4944-4

Keywords

Search

Navigation